Journal of Clinical Oncology, Vol 16, 261-268, Copyright © 1998 by American Society of Clinical Oncology
Identification of clinical stage A nonseminomatous testis cancer patients at extremely low risk for metastatic disease: a combined approach using quantitive immunohistochemical, histopathologic, and radiologic assessment
I Leibovitch, RS Foster, KK Kopecky, P Albers, TM Ulbright and JP Donohue
Department of Urology, Indiana University School of Medicine, Indianapolis 46202, USA.
PURPOSE: To evaluate previously determined predictors of metastasis in
low-stage testis cancer in a consecutive group of clinical stage A
patients. PATIENTS AND METHODS: Ninety-one consecutive clinical stage A
nonseminomatous germ cell tumor (NSGCT) patients who underwent primary
nerve-sparing retroperitoneal lymph node dissection (NSRPLND) had
orchiectomy specimens and computed tomographic (CT) scans evaluated blindly
in a quantitative fashion. These scores were then correlated with
pathologic stage using previously determined paradigms. RESULTS: Using
volume of embryonal carcinoma in the orchiectomy specimen, lymph node
diameters in the primary landing zones and MIB-1 staining of the
orchiectomy specimen, 41 patients were classified as low risk for
metastasis. Forty of these 41 had pathologic stage A disease at RPLND.
CONCLUSION: These parameters can identify a low-risk group of patients for
metastasis who can be rationally offered surveillance.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
P. Albers, R. Siener, S. Krege, H.-U. Schmelz, K.-P. Dieckmann, A. Heidenreich, P. Kwasny, M. Pechoel, J. Lehmann, S. Kliesch, et al.
Randomized Phase III Trial Comparing Retroperitoneal Lymph Node Dissection With One Course of Bleomycin and Etoposide Plus Cisplatin Chemotherapy in the Adjuvant Treatment of Clinical Stage I Nonseminomatous Testicular Germ Cell Tumors: AUO Trial AH 01/94 by the German Testicular Cancer Study Group
J. Clin. Oncol.,
June 20, 2008;
26(18):
2966 - 2972.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. J. Schmoll, R. Souchon, S. Krege, P. Albers, J. Beyer, C. Kollmannsberger, S. D. Fossa, N. E. Skakkebaek, R. de Wit, K. Fizazi, et al.
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG)
Ann. Onc.,
September 1, 2004;
15(9):
1377 - 1399.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Mazumdar, J. Bacik, S. K. Tickoo, D. Dobrzynski, A. Donadio, D. Bajorin, R. Motzer, V. Reuter, and G. J. Bosl
Cluster Analysis of p53 and Ki67 Expression, Apoptosis, Alpha-Fetoprotein, and Human Chorionic Gonadotrophin Indicates a Favorable Prognostic Subgroup Within the Embryonal Carcinoma Germ Cell Tumor
J. Clin. Oncol.,
July 15, 2003;
21(14):
2679 - 2688.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
